Immunotherapy is the concept of using the immune system to treat disease, for example, developing a vaccine against cancer. Immunotherapy may also refer to the therapy of diseases caused by the immune system, allergies for example.
Developing “super soldiers” of particular white blood cells to promote an anti-tumor reaction has been demonstrated in a series of well-designed experiments.
Recently, messenger RNA, also called mRNA, vaccines, to combat the COVID-19 infection have made headlines worldwide, but researchers have already been experimenting with mRNA vaccines to prevent or cure other illnesses, including certain types of cancer.
A Ludwig Cancer Research study has identified a novel mechanism by which a type of cancer immunotherapy known as CTLA-4 blockade can disable suppressive immune cells to aid the destruction of certain tumors.
In people with central nervous system (CNS) lymphoma, cancerous B cells--a type of white blood cell--accumulate to form tumors in the brain or spinal cord, often in close proximity to blood vessels.
Because cancers in children are rare, many details about their biology remain unknown. In the field of cancer genetics, there's a limited understanding of how inherited genetic changes may contribute to the formation and growth of tumors.
Cancer cells and immune cells share something in common: They both love sugar. Sugar is an important nutrient. All cells use sugar as a vital source of energy and building blocks. For immune cells, gobbling up sugar is a good thing, since it means getting enough nutrients to grow and divide for stronger immune responses. But cancer cells use sugar for more nefarious ends.
Statistical modeling developed by Oregon State University researchers has confirmed that changes to melanoma patients' gut microbiome led them to respond to a type of treatment capable of providing long-term benefit.
A study has revealed how chemicals surrounding tumors, the tumor microenvironment, undermine the immune system and allow cancer to resist attack.
A paper published today in Nature shows how chemicals in the areas surrounding tumors--known as the tumor microenvironment--subvert the immune system and enable cancer to evade attack. These findings suggest that an existing drug could boost cancer immunotherapy.
For all their importance as a breakthrough treatment, the cancer immunotherapies known as checkpoint inhibitors still only benefit a small minority of patients, perhaps 15 percent across different types of cancer. Moreover, doctors cannot accurately predict which of their patients will respond.
Researchers at Case Western Reserve University, using artificial intelligence (AI) to analyze simple tissue scans, say they have discovered biomarkers that could tell doctors which lung cancer patients might actually get worse from immunotherapy.
For patients with cancers that do not respond to immunotherapy drugs, adjusting the composition of microorganisms in the intestines--known as the gut microbiome--through the use of a stool, or fecal, transplants may help some of these individuals respond to the immunotherapy drugs, a new study suggests.
A City of Hope-led research team found that the same gene that increases the risk for Alzheimer's disease, ApoE4, can increase the susceptibility to and severity of COVID-19.
Scientists are hoping advances in cancer research could lead to a day when a patient's own immune system could be used to fight and destroy a wide range of tumors.
There are many mechanisms by which the body responds to foreign invaders. One of these involves the T-cells of the immune system, which have a number of different proteins on their surface called "checkpoint proteins."
It was an unexpected discovery that started with an analysis of more than 1,000 genes. The question: why game-changing cancer immunotherapy treatments work for only a fraction of patients.
News-Medical speaks to Dr. Beheshti from NASA about his latest research that investigated whether changes in mitochondria could cause health problems in Space.
Scientists from Indiana University have discovered how breast cancer cells evade immune cells to survive.
Researchers at the Francis Crick Institute, the UCL Cancer Institute, and the Cancer Research UK Lung Cancer Centre of Excellence have identified genetic changes in tumours which could be used to predict if immunotherapy drugs would be effective in individual patients.
Researchers have developed a new integrated genetic/epigenetic DNA-sequencing protocol known as MultiMMR that can identify the presence and cause of mismatch repair (MMR) deficiency in a single test from a small sample of DNA in the colon, endometrial, and other cancers.